Stereotypic neutralizing V <sub>H</sub> antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals
Sang Il Kim, Jinsung Noh, Sujeong Kim, Young Geun Choi, Duck Kyun Yoo, Yonghee Lee, Hyunho Lee, Jongtak Jung, Chang Kyung Kang, Kyoung‐Ho Song, Pyoeng Gyun Choe, Hong Bin Kim, Eu Suk Kim, Nam Joong Kim, Moon‐Woo Seong, Wan Beom Park, Myoung‐don Oh, Sunghoon Kwon, Junho Chung
Abstract
clonotypes existed in 6 of 10 healthy individuals, with IgM isotypes predominating. These findings suggest that stereotypic clonotypes can develop de novo from naïve B cells and not from memory B cells established from prior exposure to similar viruses. The expeditious and stereotypic expansion of these clonotypes may have occurred in patients infected with SARS-CoV-2 because they were already present.
Topics & Concepts
Spike ProteinCoronavirus disease 2019 (COVID-19)NeutralizationAntibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibody2019-20 coronavirus outbreakImmunityReceptorImmunologyMedicineBiologyImmune systemInfectious disease (medical specialty)Internal medicineDiseaseOutbreakSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchComplement system in diseases